Idorsia’s plans to sell its hypertension drug Tryvio have faced a speed bump ... The Swiss biopharma, which also manufactures insomnia med Quviviq, has been walking a financial tightrope ...

Idorsia will call a bondholder meeting in accordance with articles 1164 et seqq. of the Swiss Code of Obligations and will propose to the bondholders to modify the terms of the Bonds to, among others, ...

Shares in Idorsia slumped after the company said it failed to sell the rights to its hypertension treatment and that is considering alternatives that would allow it to keep operating. Shares in ...

Idorsia will announ Idorsia’s dual orexin receptor antagonist, a drug working by a new mechanism of action for the treatment of chronic insomnia, has been awarded the prestigious Prix Galien ...

Nxera Pharma Japan Co., Ltd. (a wholly owned subsidiary of Nxera Pharma) is the approval holder and will be responsible in part for provision of drug ... of Idorsia Ltd. About Insomnia Disorder ...

QUVIVIQ™ is an oral Dual Orexin Receptor Antagonist (DORA) for the treatment of insomnia that selectively ... be responsible in part for provision of drug product. Shionogi will be solely ...

discovered by Idorsia Pharmaceuticals Ltd, that blocks the binding and activity of the wake-promoting neuropeptides known as orexins. In October 2022, daridorexant achieved positive Phase 3 top-line ...